Table 1.

Clinicopathologic Features of Patients With C-Ros Oncogene 1 (ROS1) Rearrangement (n = 106)

Characteristic	ROS1 Fusion-Positive Patients (n = 106)	ROS1 Fusion-Positive Patients Treated With Crizotinib (n = 38)
Age (years)
Median	54	55
Range	26–79	26–79
Sex
Male	65 (61.32%)	15 (39.47%)
Female	41 (38.68%)	23 (60.53%)
Histologic type [n (%)]
Adenocarcinoma	100 (94.34%)	35 (92.11%)
Squamous cell carcinoma	3 (2.83%)	1 (2.63%)
Adenosquamous carcinoma	3 (2.83%)	2 (5.26%)
Disease stage [n (%)]
IIIB	8 (7.55%)	5 (13.16%)
≥ IV	98 (92.45%)	33 (86.84%)
Brain metastasis
Yes	9 (8.49%)	8 (21.05%)
No	32 (30.19%)	22 (57.89%)
Unknown	65 (61.32%)	8 (21.05%)
Concurrent driven mutation [n (%)]
EGFR mutation	2 (1.88%)	0 (0%)
ALK fusion	2 (1.88%)	0 (0%)
MET amplification	1 (0.94%)	0 (0%)
ERBB2 amplification	1 (0.94%)	0 (0%)

ALK, anaplastic lymphoma kinase; MET, MET proto-oncogene, receptor tyrosine kinase.